References
[1] Gandhi NR, Brust JCM, Sarita Shah N. A new era for treatment of drug-resistant tuberculosis. European Respiratory Journal 2018;52. https://doi.org/10.1183/13993003.01350-2018. [2] Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regi
[1] Gandhi NR, Brust JCM, Sarita Shah N. A new era for treatment of drug-resistant tuberculosis. European Respiratory Journal 2018;52. https://doi.org/10.1183/13993003.01350-2018.
[2] Ndjeka N, Schnippel K, Master I, Meintjes G, Maartens G, Romero R, et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. European Respiratory Journal 2018;52. https://doi.org/10.1183/13993003.01528-2018.
[3] Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med 2018;6:699–706. https://doi.org/10.1016/S2213-2600(18)30235-2.
[4] World Health Organization (WHO). Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis. World Health Organization 2019.
[5] National Department of Health (RSA). Interim clinical guidance for implementation of injectable-free regimens for rifampicin-resistant tuberculosis in adults, adolescents and children. Pretoria, South Africa: 2018.
[6] Ndjeka N, Hughes J, Reuter A, Conradie F, Enwerem M, Ferreira H, et al. Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn? Int J Tuberc Lung Dis 2020;24. https://doi.org/10.5588/ijtld.20.0174.
[7] World Health Organization. Rapid communication: Key changes to the treatment of drug-resistant tuberculosis. 2022.
[8] World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis. 2020.
[9] World Health Organization. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17-19 November 2020. Geneva: 2020.
[10] National Department of Health (RSA). MDR-TB: A policy framework on decentralised and deinstitutionalised management for South Africa. www.health.gov.za; 2019.
[11] National Department of Health (RSA). Management of Rifampicin-Resistant Tuberculosis: A Clinical Reference Guide. Pretoria, South Africa: 2019.
[12] World Health Organization. WHO consolidated guidelines on tuberculosis Rapid diagnostics for tuberculosis detection, 2021 update. vol. Module 3. 2021.
[13] World Health Organization. WHO consolidated guidelines on tuberculosis Module 5: Management of tuberculosis in children and adolescents. 2022.
[14] Turkova A, Wills GH, Wobudeya E, Chabala C, Palmer M, Kinikar A, et al. Shorter Treatment for Non-severe Tuberculosis in African and Indian Children. New England Journal of Medicine 2022;386. https://doi.org/10.1056/nejmoa2104535.
[15] The Sentinel Project for Pediatric Drug-Resistant Tuberculosis. Tuberculosis in children: A FIELD GUIDE. Boston, USA 2022; Fifth Edition.
[16] National Department of Health. 2023 ART Clinical Guidelines for the Management of HIV in Adults, Pregnancy, Adolescents, Children, Infants and Neonates. Pretoria: 2023.
[17] World Health Organization. WHO operational handbook: drug-resistant tuberculosis, 2022. World Health Organization: Geneva 2022.
[18] World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug - resistant tuberculosis treatment, 2022 update. World Health Organization: Geneva 2022.
[19] WHO. Consolidated Operational Guidelines on Handbook Tuberculosis. 2020.
[20] World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. WHO consolidated guidelines on Drug-Resistant Tuberculosis Treatment 2019.
[21] Koele SE, van Beek SW, Maartens G, Brust JCM, Svensson EM. Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment. Antimicrob Agents Chemother 2022;66. https://doi.org/10.1128/aac.01749-21.
[22] Conradie F, Phillips P, Badat T, Poswa A, Rajaram S, N. Nosipho, P. Howell, N Mbhele, L. Ramangoaela, S. Ntsabo, K Selibas, Ndjeka N. High rate of successful outcomes treating RR-TB with a delamanidbedaquiline regimen in BEAT Tuberculosis: an interim analysis: LBTB-2074-11 World Conference on Lung Health 2022 of The International Union Against Tuberculosis And Lung Disease Virtual event Abstract_Book_2022-compressed.pdf (theunion.org. Accessed on 15 May 2023).
[23] Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. N Engl J Med. 2020;382(10):893–902.
National Department of Health Clinical Management of Rifampicin-Resistant Tuberculosis, September 2023
References